Compounds > l 739594

Page last updated: 2024-12-08

l 739594

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 739594: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	455674
CHEMBL ID	315403
MeSH ID	M0234947

Synonyms (15)

Synonym
CHEMBL315403 ,
l-739,594
156879-13-9
carbamic acid, (3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-, hexahydrofuro(2,3-b)furan-3-yl ester, (3s-(2(1r(3s,3ar,6as),2s*),3alpha,4abeta,8abeta))-
l-739594
hexahydrofuro(2,3-b)furan-3-yl (3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)carbamate (3s-(2(1r(3s,3ar,6as),2s*),3alpha,4abeta,8abeta))-
[(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(1s,2r)-3-[(3s,4as,8as)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]carbamate
ro 31-8959-bis-thf deriv.
(3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl {(1s,2r)-1-benzyl-3-[(3s,4as,8as)-3-[(tert-butylamino)carbonyl]octahydroisoquinolin-2(1h)-yl]-2-hydroxypropyl}carbamate
l 739594
[(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-4-[(3s,4as,8as)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate
bdbm50477797
DTXSID30935553
n-tert-butyl-2-[3-({[(hexahydrofuro[2,3-b]furan-3-yl)oxy](hydroxy)methylidene}amino)-2-hydroxy-4-phenylbutyl]decahydroisoquinoline-3-carboximidic acid
AKOS040746028

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Gag-Pol polyprotein	Human immunodeficiency virus type 1 (BRU ISOLATE)	Ki	0.0020	0.0000	0.0828	3.3000	AID1796306
Gag-Pol polyprotein	Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)	IC50 (µMol)	0.0018	0.0002	0.1042	1.7000	AID1795258
Protease	Human immunodeficiency virus 1	IC50 (µMol)	0.0669	0.0001	0.2248	7.3200	AID162377
Protease	Human immunodeficiency virus 1	IC50 (µMol)	0.0018	0.0000	0.8176	9.8500	AID311574; AID415236
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Protease	Human immunodeficiency virus 1	IC95 (µMol)	0.2973	0.0060	1.0868	6.0000	AID161882; AID161887
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID415236	Inhibition of HIV1 protease	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
AID311574	Inhibition of HIV1 protease	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
AID311575	Antiviral activity against HIV1 in CEM cells	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
AID106078	Inhibition of HIV-1 replication in infected MT-4 human T-lymphoid cells.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
AID162377	Tested for inhibitory activity against HIV protease enzyme	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.
AID20907	Aqueous solubility in phosphate buffer of pH 7.4	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
AID415237	Antiviral activity against HIV1 assessed as inhibition of viral replication	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
AID161882	Tested for antiviral potency against HIV protease enzyme	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.
AID161887	Inhibitory activity against HIV-1 protease enzyme	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
AID1796306	Protease Inhibition Assay from Article 10.1016/s0960-894x(02)00300-1: \\Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.\\	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.
AID1795258	Protease Inhibition Assay from Article 10.1021/jm960128k: \\Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.\\	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (40.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.66 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (40.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	3 (60.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
tetrahydrofuran oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.	1.98	1	0	cyclic ether; oxolanes; saturated organic heteromonocyclic parent; volatile organic compound	polar aprotic solvent
amprenavir [no description available]	3.14	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
uic-94003 UIC-94003: structure in first source	4.33	3	0
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	4.05	2	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	3.14	1	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	4.02	4	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
om99-2 OM99-2: eight-residue memapsin 2 inhibitor; structure in first source	3.14	1	0
grl 98065 [no description available]	3.14	1	0
pl 100 PL 100: inhibits HIV-1 protease; structure in first source	3.13	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
HIV Coinfection [description not available]	0	3.83	2	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	0	3.83	2	0
Acute Confusional Senile Dementia [description not available]	0	2.96	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.96	1	0